cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. - Wikidata - awgldk - TriplyDB

cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity.

cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity.

http://www.wikidata.org/entity/Q34192806

about

CD30 is a potential therapeutic target in malignant mesothelioma Synthesis of site-specific antibody-drug conjugates using unnatural amino acids Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma Recent advances in the management of Hodgkin lymphoma Methods to Design and Synthesize Antibody-Drug Conjugates (ADCs)Novel Targeted Agents in Hodgkin and Non-Hodgkin Lymphoma Therapy Progress and Challenges in Developing Aptamer-Functionalized Targeted Drug Delivery Systems Antibody-drug conjugates as novel anti-cancer chemotherapeutics Site-specific functionalization of proteins and their applications to therapeutic antibodies CD30: from basic research to cancer therapy Trypanocidal activity of marine natural products Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemia Antibody drug-conjugates targeting the tumor vasculature: Current and future developments Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency Development and Evaluation of a Fluorescent Antibody-Drug Conjugate for Molecular Imaging and Targeted Therapy of Pancreatic Cancer Structural Basis of Microtubule Destabilization by Potent Auristatin Anti-Mitotics Diagnostic, prognostic and therapeutic role of CD30 in lymphoma.T-cell lymphomas, a challenging disease: types, treatments, and future.Pediatric Hodgkin lymphoma: biomarkers, drugs, and clinical trials for translational science and medicine.Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation Brentuximab vedotin: treatment role for relapsed refractory systemic anaplastic large-cell lymphoma.Recent trends in targeted anticancer prodrug and conjugate design.Dual targeting of integrin αvβ3 and matrix metalloproteinase-2 for optical imaging of tumors and chemotherapeutic delivery.Evaluation of Factors Influencing Antibody Reduction for Development of Antibody Drug Conjugates RF1 attenuation enables efficient non-natural amino acid incorporation for production of homogeneous antibody drug conjugates.Cell membrane-specific epitopes on CD30: Potentially superior targets for immunotherapy.Prodrug applications for targeted cancer therapy.Recent Advances in the Pathobiology of Hodgkin's Lymphoma: Potential Impact on Diagnostic, Predictive, and Therapeutic Strategies.Antibody-based therapeutics to watch in 2011.CD30 expression is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma, nasal type Microtubule inhibitor-based antibody-drug conjugates for cancer therapy.Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma.Protrusion-guided extracellular vesicles mediate CD30 trans-signalling in the microenvironment of Hodgkin's lymphoma.Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin.Emerging Pharmacotherapy for Relapsed or Refractory Hodgkin's Lymphoma: Focus on Brentuximab Vedotin CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin.Protease-activated drug development.Antibody-recruiting molecules: an emerging paradigm for engaging immune function in treating human disease.Hetero-modification of TRAIL trimer for improved drug delivery and in vivo antitumor activities.Brentuximab vedotin in transplant-naive patients with relapsed or refractory hodgkin lymphoma: analysis of two phase I studies.

P2860

Q23921491-9DBF21C9-7428-4F7C-ADE6-0449CC66D946 Q24624489-6AA9C2BC-5543-48E1-A4A7-669C817C444A Q24633761-A9B64960-8DA6-40B3-AA74-E4FE37B71D9E Q26751214-0665C160-D77D-4538-9353-4223E43632B4 Q26768654-FF36D148-A7B6-4D49-A8E2-DF7B35F86E96 Q26782270-F96BE5D5-C22E-4116-B81B-AA42B2767B69 Q26782485-D140D836-1912-4B71-BD4D-2BCB520CFF17 Q26800175-2E847059-2E5C-47BF-BE6A-1338A26E54DB Q26830699-7D2D2CFC-B9C4-4EB0-8776-B397D7136882 Q26859079-A465A563-BAD0-4C0D-BBE5-431A833D836D Q27008593-2FCA191A-C223-4750-88E1-6BF1C0B8A7EF Q28263993-007ACAB8-E92B-4348-8CA0-382CB7A523DB Q28270261-A0E53049-EF70-47E3-A0EB-1F9ED66D6BF6 Q28546010-86EA4E17-332C-4F7C-9369-0F9D689AA7F7 Q28552050-888AE101-8351-4954-BE17-0A06D846660A Q28553497-D5E735F2-7F4C-48F9-8EEE-0F6435C57D18 Q30240160-393CAFED-F4B5-4E5C-977D-AA5056E37F52 Q30244553-0116EBFB-9EC4-4ADE-9151-3E9C0979B641 Q30248284-2DCEF5D4-6BBA-43AB-A681-07EA3EFA21AB Q33400803-09CE5D80-EC04-45FD-BC4A-9FD4D0CBC688 Q33410081-50F8356F-F105-41A8-BA73-0F27D2C1E75D Q33573762-707E7C34-1A82-4D6C-82C8-D81887237BA8 Q33732724-2E88C392-111B-4460-ABDC-AE8D28BF78C1 Q33766408-CAB70046-14C0-4CC7-B59C-37685318BDA7 Q33780009-47AFF9DF-EF63-4089-9602-27C7B157B1EE Q33841251-D13A79A0-E24A-451F-B54D-F0905E9C2536 Q34099780-C628C3A0-944D-4AC0-9D03-84E127D995B1 Q34557179-AC30D3D7-35BA-4215-82B4-734B268F6A57 Q34570079-997A767A-DC70-4277-BDA8-6253BDB7F68A Q34650606-C1FB5DC9-0C55-4D2A-A731-B012B8F4F0A4 Q34655256-12B00C26-44B4-4117-A1C1-6D630A7EAD59 Q34778364-251042BD-F3FF-4384-9D5D-C9612345A084 Q35128470-9B298BD0-03BD-491C-9683-73237A3EC022 Q35586880-3B5FC500-2805-4398-B973-AF4A70C14621 Q35669134-F5EE88E8-43A2-4225-87CB-C5CDE644CC3D Q35691210-CB8916B0-E51A-49C0-919C-6F251A74D462 Q35811508-A59F3436-AD47-45B7-9A0A-1AA7B8E7FBE9 Q36108119-8E529D4C-E5E6-4869-97C9-62009F5AD715 Q36134152-B425CAD7-B17E-4AA7-BD06-1EC74EE9FCA5 Q36182830-C4E31709-4AE9-4082-AABA-65403FAD3E94

P2860

cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity.

http://www.wikidata.org/entity/Q34192806

description

2003 nî lūn-bûn

@nan

2003 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

name

cAC10-vcMMAE, an anti-CD30-mon ...... selective antitumor activity.

@ast

cAC10-vcMMAE, an anti-CD30-mon ...... selective antitumor activity.

@en

cAC10-vcMMAE, an anti-CD30-mon ...... selective antitumor activity.

@nl

type

label

cAC10-vcMMAE, an anti-CD30-mon ...... selective antitumor activity.

@ast

cAC10-vcMMAE, an anti-CD30-mon ...... selective antitumor activity.

@en

cAC10-vcMMAE, an anti-CD30-mon ...... selective antitumor activity.

@nl

prefLabel

cAC10-vcMMAE, an anti-CD30-mon ...... selective antitumor activity.

@ast

cAC10-vcMMAE, an anti-CD30-mon ...... selective antitumor activity.

@en

cAC10-vcMMAE, an anti-CD30-mon ...... selective antitumor activity.

@nl

P1433

Q34192806-2602CA2F-5182-4103-ABC8-760F528F3C29

P1476

Q34192806-73F47A43-9EE6-4B7E-8217-97E4E10F1C8A

P2093

Q34192806-1FF529AC-5F35-4B3D-85F5-6FEEA962114A

Q34192806-4FCEFF54-4AC9-4A87-AE15-AFD407DB945B

Q34192806-5B2D0A2B-1BB8-4D8F-9E5B-26C77C21FECF

Q34192806-5E2F5D79-EB15-42B0-8F3D-1B142213D267

Q34192806-71BE5F4C-38FE-43CB-932D-ECFDB040F1B7

Q34192806-797820FC-A445-482E-8AFF-49C6A88672DB

Q34192806-89301462-85EE-4E34-A4DB-238075386341

Q34192806-8F87260A-2599-4DDB-A3C6-EC73EF4BE040

Q34192806-91849999-C804-40CE-8E94-7E1C67709B08

Q34192806-B5DD3689-E6C0-4DD5-850D-4B6C49387BE3

P304

Q34192806-FBC5DD5F-1A41-4E8D-86A8-7332D55DCB31

P31

Q34192806-3EB41F1A-4900-495B-9CAD-F8CBAB2E184A

P356

Q34192806-38061622-ABBF-425C-8F78-EF4900197A21

P407

Q34192806-F25CD0DB-1174-4EEE-89D3-726F7EE8C526

P433

Q34192806-6A45E0CF-63B8-4CB7-8EF3-CFB6096E6890

P478

Q34192806-64CEB5B1-0984-406C-B709-56B2AFF5E2C8

P577

Q34192806-11D2EA1C-4CA0-41C7-8E51-A2BB721943B4

P5875

Q34192806-3D22A654-1AD5-4DE3-9CAB-6F0FB7E6B7FD

P698

Q34192806-4B4CE542-7E49-4FFA-B02E-3F515416A3E7

P356

BLOOD-2003-01-0039

P1433

P1476

cAC10-vcMMAE, an anti-CD30-mon ...... selective antitumor activity.

@en

P2093

Alan F Wahl

http://www.w3.org/2001/XMLSchema#string

Brian E Toki

http://www.w3.org/2001/XMLSchema#string

Bruce J Mixan

http://www.w3.org/2001/XMLSchema#string

Charles G Cerveny

http://www.w3.org/2001/XMLSchema#string

Che-Leung Law

http://www.w3.org/2001/XMLSchema#string

Clay B Siegall

http://www.w3.org/2001/XMLSchema#string

Damon L Meyer

http://www.w3.org/2001/XMLSchema#string

Dana F Chace

http://www.w3.org/2001/XMLSchema#string

Joseph A Francisco

http://www.w3.org/2001/XMLSchema#string

Kerry Klussman

http://www.w3.org/2001/XMLSchema#string

P304

1458-1465

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2003-01-0039

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

102

http://www.w3.org/2001/XMLSchema#string

P577

2003-04-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10787023

http://www.w3.org/2001/XMLSchema#string

P698

12714494

http://www.w3.org/2001/XMLSchema#string